Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leukemia

Trial Profile

Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Fludarabine; Mitoxantrone
  • Indications T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 05 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by the ClinicalTrials.gov record.
    • 13 Jul 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2008-001421-34).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top